According to a recent study in Human Reproduction, women who produce a low number of oocytes during in vitro fertilization (IVF) seem to have an increased risk of miscarriage.
According to a recent study in Human Reproduction, women who produce a low number of oocytes during in vitro fertilization (IVF) seem to have an increased risk of miscarriage.
Researchers at the University of Birmingham looked at data from the Human Fertilization and Embryology Authority, collected from 1991 to June 2008, covering 402,185 stimulated fresh IVF cycles and 124,351 resulting pregnancies.
A strong association between the number of oocytes retrieved per IVF cycle and the clinical miscarriage rate was found. Logistic regression identified 3 cut-off points where the probability of clinical miscarriage fell: 4, 10, and 15 oocytes. Women who produced <4 oocytes had a miscarriage rate of 20%; the miscarriage rate was 15.5% for women who produced between 4 and 9 oocytes; and women with 10 to 14 oocytes had a miscarriage rate of 13.8%. No increase in miscarriage risk was found in women who produced very high numbers of oocytes (>20 oocytes). The lowest risk of miscarriage was found in women younger than age 38, with primary infertility without a female cause, and who produced more than 3 oocytes.
The investigators said that the data were limited by a lack of information on the total gonadotropin consumption and confounders such as body mass index. They also concluded that the high rate of miscarriage is more than likely associated with a decline in the quality of the oocytes.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More